Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04464395 · ClinicalTrials.gov registry record · Phase 1
Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients
A Phase 1 study, sponsored by Corvus Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT04464395 is a Phase 1 study that has completed, run by Corvus Pharmaceuticals. The registered enrollment target is 30 participants.
The verdict
NCT04464395, a Phase 1 study, has completed, sponsored by Corvus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This Phase 1 single-dose, dose-escalation study is an open label trial evaluating the safety of CPI-006, a humanized monoclonal antibody targeting the CD73 cell-surface ectonucleotidase, as immunotherapy for stable hospitalized mild or moderately symptomatic COVID-19 patients with a parallel non-randomized Control Arm for treatment with standard of care only.
Interventions
- OTHER Standard of Care
- DRUG CPI-006
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-07-01 |
| Est. Completion | 2021-07-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04464395
The ClinicalTrials.gov registry entry for NCT04464395 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corvus Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT04464395 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04464395 about?
NCT04464395 is a clinical study titled "Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients". This Phase 1 single-dose, dose-escalation study is an open label trial evaluating the safety of CPI-006, a humanized monoclonal antibody targeting the CD73 cell-surface ectonucleotidase, as immunotherapy for stable hospitalized mild or moderately symptomatic COVID-19 patients with a parallel non-ran...
What is the current status of trial NCT04464395?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2020-07-01. Estimated completion is 2021-07-09.
What interventions are being tested in trial NCT04464395?
The interventions under investigation include: Standard of Care (OTHER), CPI-006 (DRUG).
Who is sponsoring clinical trial NCT04464395?
This trial is sponsored by Corvus Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.